Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data

Alexander E Rock,1 Jeremy Lerner,2 Melissa E Badowski1 1University of Illinois, College of Pharmacy, Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, Chicago, IL 60612, USA; 2University of Illinois, College of Pharmacy, Department of Pharmacy Practice, Chicago, IL 606...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rock AE, Lerner J, Badowski ME
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	doravirine hiv-1 antiretroviral therapy non-nucleoside reverse transcriptase inhibitor Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/6b786ca651b64a9ba953e2d36b977853
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6b786ca651b64a9ba953e2d36b977853
record_format	dspace
spelling	oai:doaj.org-article:6b786ca651b64a9ba953e2d36b9778532021-12-02T10:31:22ZDoravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data1179-1373https://doaj.org/article/6b786ca651b64a9ba953e2d36b9778532020-06-01T00:00:00Zhttps://www.dovepress.com/doravirine-and-its-potential-in-the-treatment-of-hiv-an-evidence-based-peer-reviewed-article-HIVhttps://doaj.org/toc/1179-1373Alexander E Rock,1 Jeremy Lerner,2 Melissa E Badowski1 1University of Illinois, College of Pharmacy, Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, Chicago, IL 60612, USA; 2University of Illinois, College of Pharmacy, Department of Pharmacy Practice, Chicago, IL 60612, USACorrespondence: Melissa E BadowskiUniversity of Illinois, College of Pharmacy, Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, 833 S. Wood, Room164, MC886, Chicago, IL 60612, USAEmail Badowski@uic.eduAbstract: The utility of doravirine in the management of HIV-1 infection is approved for use in patients who are antiretroviral-naïve as well as patients who have achieved stable virologic suppression and are interested in replacing their current antiretroviral therapy. The role of doravirine continues to evolve as data emerges on the potential for new combination therapy with the investigational agent, islatravir, as well as a potential strategy to minimize post-marketing safety concerns with recommended first-line agents, such as integrase inhibitors. The goal of this review is to assess recent and emerging data on the non-nucleoside reverse transcriptase inhibitor, doravirine.Keywords: doravirine, HIV-1, antiretroviral therapy, non-nucleoside reverse transcriptase inhibitorRock AELerner JBadowski MEDove Medical Pressarticledoravirinehiv-1antiretroviral therapynon-nucleoside reverse transcriptase inhibitorImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol Volume 12, Pp 201-210 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	doravirine hiv-1 antiretroviral therapy non-nucleoside reverse transcriptase inhibitor Immunologic diseases. Allergy RC581-607
spellingShingle	doravirine hiv-1 antiretroviral therapy non-nucleoside reverse transcriptase inhibitor Immunologic diseases. Allergy RC581-607 Rock AE Lerner J Badowski ME Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
description	Alexander E Rock,1 Jeremy Lerner,2 Melissa E Badowski1 1University of Illinois, College of Pharmacy, Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, Chicago, IL 60612, USA; 2University of Illinois, College of Pharmacy, Department of Pharmacy Practice, Chicago, IL 60612, USACorrespondence: Melissa E BadowskiUniversity of Illinois, College of Pharmacy, Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, 833 S. Wood, Room164, MC886, Chicago, IL 60612, USAEmail Badowski@uic.eduAbstract: The utility of doravirine in the management of HIV-1 infection is approved for use in patients who are antiretroviral-naïve as well as patients who have achieved stable virologic suppression and are interested in replacing their current antiretroviral therapy. The role of doravirine continues to evolve as data emerges on the potential for new combination therapy with the investigational agent, islatravir, as well as a potential strategy to minimize post-marketing safety concerns with recommended first-line agents, such as integrase inhibitors. The goal of this review is to assess recent and emerging data on the non-nucleoside reverse transcriptase inhibitor, doravirine.Keywords: doravirine, HIV-1, antiretroviral therapy, non-nucleoside reverse transcriptase inhibitor
format	article
author	Rock AE Lerner J Badowski ME
author_facet	Rock AE Lerner J Badowski ME
author_sort	Rock AE
title	Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
title_short	Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
title_full	Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
title_fullStr	Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
title_full_unstemmed	Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
title_sort	doravirine and its potential in the treatment of hiv: an evidence-based review of the emerging data
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/6b786ca651b64a9ba953e2d36b977853
work_keys_str_mv	AT rockae doravirineanditspotentialinthetreatmentofhivanevidencebasedreviewoftheemergingdata AT lernerj doravirineanditspotentialinthetreatmentofhivanevidencebasedreviewoftheemergingdata AT badowskime doravirineanditspotentialinthetreatmentofhivanevidencebasedreviewoftheemergingdata
_version_	1718397115074347008

Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data

Ejemplares similares